Roflumilast Cream 0.05% Performs Well in Pediatric Eczema
Roflumilast cream 0.05% (Zoryve, Arcutis Biotherapeutics, Inc.) improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints in kids aged 2 to 5, according to the INTEGUMENT-PED Trial. Roflumilast cream is a next-generation topical phosphodiesterase 4 (PDE4) inhibitor. Roflumilast cream 0.3% is […]